Annual Report 2003 Aventis - Sanofi
Annual Report 2003 Aventis - Sanofi
Annual Report 2003 Aventis - Sanofi
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
Medical Background<br />
Diabetes mellitus is a condition where the body<br />
does not produce, or properly use insulin, the hormone<br />
needed to convert glucose (sugar) into energy.<br />
In a healthy, non-diabetic person, insulin acts to<br />
convert glucose (created when sweet and starchy<br />
foods are digested) into the energy needed to perform<br />
daily tasks. People with diabetes do not have<br />
enough insulin and/or are insulin-resistant and are<br />
thus unable to make this necessary conversion into<br />
energy. They therefore have high levels of unused<br />
glucose in their system, which is referred to as high<br />
blood glucose or hyperglycemia.<br />
In type 1 diabetes there is a complete defi ciency<br />
in insulin production and secretion. Impaired insulin<br />
secretion occurs when a person’s immune system<br />
attacks and destroys the beta cells in the pancreas.<br />
Therefore, type 1 diabetes is called an autoimmune<br />
disease. People with type 2 diabetes have a condition<br />
referred to as relative insulin defi ciency. While the pancreas<br />
is making insulin, there is not enough insulin<br />
being produced to adequately control glucose levels.<br />
<strong>Aventis</strong> approaches to treat diabetes<br />
Type I<br />
Type II<br />
Food<br />
Glucose<br />
Immunomodulator:<br />
DiaPep277<br />
Pancreas<br />
Pancreas<br />
Sulphonylurea:<br />
Amaryl<br />
Beta cell Beta cell<br />
destroyed<br />
Lipid<br />
cell<br />
GLP-1 Receptor<br />
agonist:<br />
AVE-0010<br />
Insulins:<br />
Lantus<br />
Apidra<br />
Exubera<br />
>> 18